Renier Brentjens

Co-Founder JUNO Therapeutics. Director, Cell Therapy Memorial Sloan-Kettering (MSK). As a medical oncology fellow at MSK Cancer Center, Dr. Brentjens began the first studies that demonstrated the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors (CARs). Work in his lab expanded this technology to target additional tumor antigens.